Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2023-05-25 AGM Information
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma i SynAct Pharma AB den 25 maj 2023
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämma i SynAct Pharma AB den 25 maj 2023" (Communiqué from the Annual General Meeting in SynAct Pharma AB on May 25, 2023). It details the resolutions passed at the meeting, including financial approvals, board elections, remuneration, changes to the articles of association, and authorization for share issues. This content directly corresponds to the materials and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2023-05-25 Swedish
SynAct Pharma utser Björn Westberg till CFO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (CFO), Björn Westberg, to SynAct Pharma AB. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is short and focuses entirely on this personnel change, not on financial results (ER/IR) or regulatory filings (10-K/AR). Therefore, the appropriate code is MANG.
2023-05-15 Swedish
SynAct Pharma appoints Björn Westberg as CFO
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (CFO), Björn Westberg, and mentions the departure of the previous CFO. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). The document is short (3141 characters) and is an announcement, not a comprehensive report like a 10-K or IR. It fits the MANG category perfectly.
2023-05-15 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for SynAct Pharma AB for the first quarter of 2023. It contains comprehensive financial statements (income statement, balance sheet, cash flow), management commentary, and operational updates. It is clearly a full quarterly report rather than an announcement or a summary, as it spans multiple pages and includes detailed financial tables and notes. Q1 2023
2023-05-05 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first quarter 2023' and contains comprehensive financial statements, including income statements, balance sheets, cash flow reports, and notes for the period ending March 31, 2023. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-05 English
SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis
Regulatory Filings Classification · 95% confidence The document announces the completion of patient recruitment for a clinical trial (EXPAND study) and provides an update on the timeline for releasing top-line data. It mentions that the information is being made public pursuant to the EU Market Abuse Regulation and includes contact details and an 'About' section, characteristic of a press release or regulatory announcement. Crucially, the document ends with an 'Attachments' section listing a PDF link, and the document length is relatively short (4961 characters). This structure strongly suggests it is an announcement *about* a development, rather than the full financial report (like 10-K or IR) or a detailed management discussion (MDA). Since it is a general regulatory announcement concerning company progress that doesn't fit specific categories like DIV, CAP, or MANG, the most appropriate classification based on the provided definitions and the 'Menu vs Meal' rule (announcement of information) is Regulatory Filing (RNS), as it serves as a general regulatory update.
2023-04-24 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.